Shares of Royalty Pharma plc (NASDAQ:RPRX – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the five research firms that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating on the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $41.80.
Several equities analysts have commented on the company. UBS Group downgraded Royalty Pharma from a “buy” rating to a “neutral” rating and set a $28.00 price objective on the stock. in a research report on Monday, June 3rd. Morgan Stanley upped their price target on shares of Royalty Pharma from $48.00 to $51.00 and gave the stock an “overweight” rating in a report on Thursday, July 11th. Bank of America decreased their price objective on shares of Royalty Pharma from $40.00 to $38.00 and set a “buy” rating for the company in a report on Friday, April 12th. Finally, StockNews.com cut shares of Royalty Pharma from a “buy” rating to a “hold” rating in a report on Friday, May 10th.
Get Our Latest Report on Royalty Pharma
Institutional Investors Weigh In On Royalty Pharma
Royalty Pharma Stock Performance
Shares of NASDAQ:RPRX opened at $28.79 on Friday. The company has a current ratio of 12.52, a quick ratio of 12.52 and a debt-to-equity ratio of 0.62. The company has a market capitalization of $17.20 billion, a price-to-earnings ratio of 21.49, a PEG ratio of 3.78 and a beta of 0.46. Royalty Pharma has a 12 month low of $25.20 and a 12 month high of $31.66. The firm’s 50-day moving average is $26.98 and its 200 day moving average is $28.40.
Royalty Pharma (NASDAQ:RPRX – Get Free Report) last released its earnings results on Thursday, May 9th. The biopharmaceutical company reported $0.98 EPS for the quarter, beating analysts’ consensus estimates of $0.96 by $0.02. Royalty Pharma had a return on equity of 22.94% and a net margin of 35.70%. The firm had revenue of $568.00 million for the quarter, compared to analysts’ expectations of $671.45 million. During the same quarter in the prior year, the firm posted $1.60 earnings per share. Research analysts predict that Royalty Pharma will post 4.01 EPS for the current year.
Royalty Pharma Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Friday, September 13th. Shareholders of record on Friday, August 16th will be paid a $0.21 dividend. This represents a $0.84 dividend on an annualized basis and a yield of 2.92%. The ex-dividend date of this dividend is Friday, August 16th. Royalty Pharma’s dividend payout ratio (DPR) is presently 62.69%.
Royalty Pharma Company Profile
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.
Read More
- Five stocks we like better than Royalty Pharma
- How to Evaluate a Stock Before Buying
- Why Call Options Volume for These 2 Stocks Spiked Together
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- MarketBeat Week in Review – 7/22 – 7/26
- What is the Australian Securities Exchange (ASX)
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
Receive News & Ratings for Royalty Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Royalty Pharma and related companies with MarketBeat.com's FREE daily email newsletter.